Ibrance is the brand name for palbociclib, a CDK4/6 inhibitor manufactured by Pfizer. Palbociclib works by blocking cyclin-dependent kinases 4 and 6, proteins that drive cancer cell division, slowing tumor growth in combination with hormone therapy. The FDA granted initial accelerated approval to palbociclib in February 2015 for hormone receptor-positive (HR+), HER2-negative advanced or metastatic breast cancer in postmenopausal women, converting to regular approval and expanding indications through 2019. Ibrance is used in combination with aromatase inhibitors such as letrozole or anastrozole, or with fulvestrant, and is approved for both women and men with HR+/HER2- metastatic breast cancer.
Palbociclib is available only through a specialty pharmacy distribution network, not at standard retail chain pharmacies. Pfizer distributes Ibrance through authorized specialty pharmacies including CVS Specialty, Walgreens Specialty, and Accredo, among others. The 2026 list price per 21-capsule pack (covering the standard 21-days-on, 7-days-off cycle) ranges from approximately $13,200 at 75 mg to $16,500 at 125 mg depending on the dose prescribed. Patients on Medicare Part D face the 2026 annual out-of-pocket cap of $2,000 across all covered drugs, which meaningfully limits exposure for a drug at this price level. The Pfizer Oncology Together savings programs, including a commercial copay card and an income-based patient assistance program, are the primary cost-reduction tools for patients without Medicare.
Ibrance (palbociclib) was selected for Round 2 of Medicare drug price negotiation under the Inflation Reduction Act. The Centers for Medicare and Medicaid Services finalized a Maximum Fair Price of $7,871 for a 30-day supply, representing a 50 percent reduction from the pre-negotiation list price of $15,741. The negotiated price takes effect January 1, 2027, not 2026. Patients receiving Ibrance on Medicare Part D in 2026 pay under the existing formulary tier structure, subject to the $2,000 annual out-of-pocket cap. Starting January 1, 2027, Medicare enrollees will benefit from the reduced Maximum Fair Price. CMS has identified palbociclib as one of four oncology agents among the 15 Round 2 selected drugs, reflecting the outsized burden specialty cancer drugs place on Medicare beneficiaries.
What Ibrance Costs by Point of Pay (2026)
The price you pay depends almost entirely on WHERE you pay. The same ibrance can cost many times more at a hospital than at your local pharmacy:
2026 Ibrance Price by Point of Pay| Where you pay | Typical cost | Notes |
|---|
| Specialty pharmacy counter (cash, no insurance) | $13,200 - $16,500 per 21-28 day supply (2026) | Dose-dependent. Available only through authorized specialty pharmacy networks, not retail chains. |
| Medicare Part D (2026) | $0 - $700/month, capped at $2,000/year total OOP | Prior authorization required. Once you hit $2,000 in annual Part D OOP, all covered drugs are $0 for the rest of the year. |
| Commercial insurance with Pfizer copay card | $0/month (up to $10,000/year in copay savings) | For commercially-insured patients only. Medicare, Medicaid, TRICARE, and VA patients are ineligible per anti-kickback statute. |
| Pfizer Oncology Together PAP (uninsured, income-qualified) | $0 (free medication for eligible patients) | For uninsured or government-underinsured patients at or below 300% FPL. Enrollment via pfizeroncologytogether.com. |
| Medicaid (where covered) | $1 - $8/prescription, with prior authorization | Coverage for metastatic breast cancer treatment varies by state formulary. Check your state's Medicaid drug list. |
Retail cash prices reflect 2026 specialty pharmacy list price. Part D ranges depend on your plan's formulary tier and where you are in your benefit year. Starting January 1, 2027, the IRA Maximum Fair Price of $7,871 applies for Medicare enrollees.
Source: Pfizer specialty pharmacy list, CMS Part D 2026 benefit design, CMS IRA Round 2 negotiated prices (IPAY 2027)
Why Hospitals Charge So Much
Ibrance is taken at home as an oral capsule or tablet, so hospital facility charges for Ibrance are uncommon during outpatient cancer treatment. When Ibrance does appear on a hospital bill, it is typically during an inpatient admission for a complication of cancer or chemotherapy, such as neutropenia (low white blood cell count). In that setting, hospitals charge a facility-rate price that can be two to four times the specialty pharmacy acquisition cost. A single month's supply at a hospital acquisition cost of roughly $10,000 to $12,000 could carry a chargemaster price of $20,000 to $45,000 before insurance adjustments.
Three factors drive hospital pricing above specialty pharmacy cost. First, hospitals apply a facility overhead markup that covers pharmacy staff, compounding rooms, and medication management infrastructure. Second, Ibrance dispensed from a hospital's own in-house specialty pharmacy carries additional handling fees not present in community specialty pharmacy billing. Third, if an inpatient stay includes Ibrance as part of a bundled admission for chemotherapy-related complications, the drug charge may be bundled into the DRG rather than billed separately, making individual line-item disputes more complicated. Patients who receive an itemized bill listing Ibrance at more than $15,741 (the 2026 pre-negotiation list price equivalent) should request the acquisition cost documentation and compare against the CMS Average Manufacturer Price for palbociclib.
Patient Assistance Programs
Pfizer operates two primary financial assistance programs for Ibrance through Pfizer Oncology Together. Without insurance, a single month of Ibrance costs $13,200 to $16,500 at 2026 list prices. The Pfizer Patient Assistance Program can reduce that cost to $0 for eligible uninsured or government-underinsured patients. For commercially insured patients, the Pfizer Oncology Together Co-Pay Savings Card can cap out-of-pocket cost at $0 per month, up to $10,000 per calendar year.
Patient assistance programs for Ibrance| Manufacturer program | Cost / Benefit | How to apply |
|---|
| Pfizer Oncology Together Co-Pay Savings Card (manufacturer coupon) | $0/month for eligible commercially insured patients (up to $10,000/year in copay savings) | pfizeroncologytogether.com |
| Pfizer Oncology Together Patient Assistance Program | Free Ibrance for uninsured or government-underinsured patients at or below 300% FPL | pfizeroncologytogether.com/patient/financial-assistance |
| PAN Foundation (Patient Access Network) | Co-pay and cost-sharing assistance for Medicare patients with qualifying income; grant amounts vary | panfoundation.org |
| NeedyMeds Drug Discount Card | Variable discount; applicable primarily for lower-cost generic alternatives when available | needymeds.org |
Manufacturer copay savings cards are not available to patients on Medicare, Medicaid, TRICARE, or VA benefits under the federal anti-kickback statute (42 U.S.C. section 1320a-7b). If you have Medicare or Medicaid, apply for the income-based Pfizer Oncology Together Patient Assistance Program instead, or contact the PAN Foundation for Medicare-specific grants.
Source: Pfizer Oncology Together (pfizeroncologytogether.com), PAN Foundation (panfoundation.org), NeedyMeds.org
Medicare Part D
Ibrance is covered under Medicare Part D as a specialty-tier prescription drug. All Medicare Part D plans are required to cover Ibrance for its FDA-approved indications: hormone receptor-positive, HER2-negative advanced or metastatic breast cancer. Prior authorization is almost universally required, and your prescribing oncologist will need to submit clinical documentation. In 2026, your total annual out-of-pocket cost for all Part D drugs combined is capped at $2,000 under the Inflation Reduction Act of 2022. Given Ibrance's high list price, most Medicare Part D enrollees will reach the $2,000 cap early in the benefit year, after which they pay $0 for covered drugs for the remainder of the year.
Medicare patients who struggle with high upfront Part D costs early in the plan year can enroll in the Medicare Prescription Payment Plan, available since 2025. This program lets you spread your annual out-of-pocket Part D costs evenly across 12 months rather than paying a large sum in January or February when a high-cost drug like Ibrance triggers rapid movement through the benefit phases. Ask your Part D plan administrator to enroll you before the plan year begins. Medicare Extra Help (the Low-Income Subsidy program) can also substantially reduce costs for beneficiaries below 150 percent of the federal poverty level, often to $0 copay or a few dollars per fill.
Starting January 1, 2027, Medicare enrollees will benefit from the IRA Round 2 Maximum Fair Price of $7,871 per 30-day supply for palbociclib, a 50 percent reduction from the pre-negotiation list price of $15,741. In 2026, that price reduction is not yet in effect. Patients who reach the $2,000 annual OOP cap in 2026 are already paying $0 for the remainder of the year, meaning the 2027 MFP primarily benefits patients who do not reach the cap, or who are enrolled in plans where their plan-paid portion shifts. Always confirm formulary tier and coverage requirements directly with your Part D plan before filling any new specialty prescription.
Common Ibrance Billing Errors
If you receive a bill for Ibrance that seems too high, or if your claim was denied, check for these common billing and coverage errors before paying:
- Prior authorization not submitted or expired: Ibrance requires PA from virtually all insurers. If your oncologist's office submitted an initial PA but it lapsed, a refill may be denied or billed at cash price. Verify PA status before every fill.
- Wrong dosage strength billed: Ibrance comes in 75 mg, 100 mg, and 125 mg capsules, and as 75 mg, 100 mg, 125 mg tablets. A billing code for the wrong strength creates a claim mismatch and potential denial.
- Charged above the $2,000 Part D OOP cap in 2026: once you reach $2,000 in out-of-pocket spending across all Part D drugs in a calendar year, you owe $0 for covered drugs. If your pharmacy charges a copay after that threshold is hit, the charge is an error.
- Copay card not applied for commercially insured patients: the Pfizer Oncology Together Co-Pay Savings Card can cap costs at $0 per month for eligible commercial-insurance patients. If the card is not on file at your specialty pharmacy, you may pay unnecessary out-of-pocket costs. Ask your specialty pharmacy to re-run the claim with the card.
- Non-participating specialty pharmacy used: Ibrance is distributed through an authorized network. Using a pharmacy outside the network may result in a full cash-price bill or insurance denial. Verify your pharmacy's network status with Pfizer Oncology Together at 1-877-744-5675.
Frequently Asked Questions
Is there a generic version of Ibrance (palbociclib) available in 2026?
No. No FDA-approved generic palbociclib is available as of 2026. Pfizer holds a U.S. patent term extension protecting Ibrance through approximately March 2027. Eight generic manufacturers have received tentative FDA approvals and are waiting for patent resolution before launching. Generic palbociclib is expected to enter the market in late 2027 or 2028, at which point prices are expected to fall 80 to 90 percent from the current branded list price. Kisqali (ribociclib) and Verzenio (abemaciclib) are other brand-name CDK4/6 inhibitors that may be formulary-preferred alternatives at your plan, but they are not equivalent generics. Ask your oncologist before switching.
How do I apply for the Pfizer Oncology Together patient assistance program for Ibrance?
Call Pfizer Oncology Together at 1-877-744-5675 (Monday through Friday, 8 am to 8 pm ET) or visit pfizeroncologytogether.com/patient/financial-assistance. Download the Patient Assistance Program enrollment form, have your oncologist complete and sign the prescriber section, and gather: proof of household income (tax return or 3 months of pay stubs), proof of U.S. residency, your Ibrance prescription, and documentation of your insurance status. Submit by fax to 1-877-736-6506 or through the online portal at patientsupportnow.org. Processing takes 7 to 14 business days. If approved, Ibrance ships free to your oncologist's office or a designated specialty pharmacy. Eligibility is limited to uninsured or government-underinsured patients at or below 300 percent of the federal poverty level.
Can I use the Pfizer Oncology Together copay savings card with Medicare?
No. The Pfizer Oncology Together Co-Pay Savings Card is for commercially insured patients only. Federal anti-kickback statute (42 U.S.C. section 1320a-7b) prohibits manufacturer copay cards from being used by Medicare, Medicaid, TRICARE, or VA beneficiaries. If you are on Medicare and struggling with Ibrance costs, your options are: (1) the income-based Pfizer Oncology Together Patient Assistance Program for government-underinsured patients at or below 300 percent of FPL; (2) PAN Foundation grants for Medicare patients with qualifying income; (3) Medicare Extra Help (Low Income Subsidy) if your income is below 150 percent of FPL; and (4) the 2026 Part D annual out-of-pocket cap of $2,000, which means most Medicare patients on Ibrance will reach the cap early in the year and pay $0 thereafter.
What if my insurance denies coverage for Ibrance?
A denial is not final. Request the written denial and the specific reason. Have your oncologist submit a letter of medical necessity citing your HR+/HER2- pathology, NCCN guideline support for CDK4/6 inhibitors as first-line combination therapy, and any contraindications to required step-therapy drugs. File a formal internal appeal within the plan's deadline (typically 60 days). If the internal appeal is denied, escalate to an external independent review through your state's Department of Insurance or, for Medicare Part D, through the Medicare Independent Review Entity. Most oncology prior authorization denials are overturned when strong clinical documentation accompanies the appeal. If appeals fail, apply for the Pfizer Oncology Together Patient Assistance Program.
What is the IRA negotiated price for Ibrance, and when does it take effect?
Under the Inflation Reduction Act of 2022, Ibrance (palbociclib) was selected for Round 2 of Medicare drug price negotiation. The Centers for Medicare and Medicaid Services finalized a Maximum Fair Price of $7,871 for a 30-day supply, down from a pre-negotiation list price of $15,741, a 50 percent reduction. The Maximum Fair Price takes effect January 1, 2027, not 2026. In 2026, Medicare patients pay under the current Part D formulary tier structure, subject to the $2,000 annual out-of-pocket cap. The 2027 price reduction will primarily benefit Medicare patients who would not otherwise reach the OOP cap.
What does Ibrance cost without insurance at a specialty pharmacy in 2026?
At 2026 list prices, Ibrance costs approximately $13,200 per 21-capsule pack at 75 mg and $16,500 per 21-capsule pack at 125 mg from authorized specialty pharmacies including CVS Specialty, Walgreens Specialty, and Accredo. The drug is not available at standard retail pharmacy chains such as Walmart or standard Kroger locations. GoodRx discounts have limited applicability for specialty drugs in restricted distribution networks. The most effective path to $0 cost without insurance is the Pfizer Oncology Together Patient Assistance Program for patients at or below 300 percent of the federal poverty level.
Do I qualify for the Pfizer Oncology Together patient assistance program?
To qualify for the Pfizer Oncology Together Patient Assistance Program and receive free Ibrance, you must meet all of these criteria: (1) your annual household income is at or below 300 percent of the federal poverty level (for example, at or below $47,880 for a household of 1, or $99,000 for a household of 4 in 2026); (2) you are uninsured or have government insurance such as Medicare or Medicaid but cannot afford your out-of-pocket costs; (3) you are a U.S. resident and are treated by a U.S.-licensed oncologist in an outpatient setting; (4) you have a valid Ibrance prescription for an FDA-approved indication (HR+/HER2- advanced or metastatic breast cancer). Commercially insured patients are not eligible for the PAP; they should use the Co-Pay Savings Card instead.
How does Ibrance compare to other CDK4/6 inhibitors like Kisqali and Verzenio?
Ibrance (palbociclib, Pfizer), Kisqali (ribociclib, Novartis), and Verzenio (abemaciclib, Eli Lilly) are all CDK4/6 inhibitors approved for HR+/HER2- advanced or metastatic breast cancer, but they have different dosing schedules, side-effect profiles, and formulary tier placements. Ibrance uses a 21-days-on, 7-days-off schedule; abemaciclib is taken continuously twice daily; ribociclib uses a 21-days-on, 7-days-off schedule but with different dosing options. Cost comparison depends entirely on your specific formulary tier: your plan may prefer one over the others, which can make a significant difference in your copay. Ask your oncologist and your insurance plan which CDK4/6 inhibitor has the lowest tier (lowest copay) under your current formulary tier structure without sacrificing the most appropriate clinical choice for your specific cancer profile.
